Schwartz Kenneth S, Lee Richard K, Gedde Steven J
Georgetown University Hospital, Washington Hospital Center, Washington, District of Columbia, USA.
Curr Opin Ophthalmol. 2006 Apr;17(2):181-9. doi: 10.1097/01.icu.0000193080.55240.7e.
The purpose of this review is to critically compare the various glaucoma drainage implants in popular use.
Glaucoma drainage implants are being increasingly utilized in the surgical management of glaucoma. Comparisons between the various drainage implants are difficult because most clinical data are derived from retrospective studies with different study populations, follow-up periods, and criteria defining success. The type of glaucoma under treatment is a major factor influencing surgical outcomes. The resistance to aqueous flow through glaucoma drainage implants occurs across the fibrous capsule around the end plate, and the major determinants of the final intraocular pressure are capsular thickness and filtration surface area. The use of antifibrotic agents as adjuncts to drainage implant surgery has not proven effective in modulating capsular thickness. Valved implants appear to reduce, but do not eliminate, the risk of hypotony. Bleb encapsulation is more frequently seen with the Ahmed valve implant than other drainage implants. Diplopia was a common complication with the Baerveldt glaucoma implant after its introduction, but design modifications have markedly reduced the incidence of this complication.
There are several glaucoma drainage implants that are currently available, and all have been shown to be safe and effective in reducing intraocular pressure. Greater pressure reduction may be achieved with implants with larger end plates, and valved implants appear to reduce the risk of postoperative hypotony.
本综述的目的是对目前常用的各种青光眼引流植入物进行批判性比较。
青光眼引流植入物在青光眼的手术治疗中应用越来越广泛。由于大多数临床数据来自不同研究人群、随访期和成功定义标准的回顾性研究,因此对各种引流植入物进行比较很困难。所治疗的青光眼类型是影响手术结果的主要因素。房水通过青光眼引流植入物的阻力发生在终板周围的纤维囊,最终眼压的主要决定因素是囊膜厚度和滤过表面积。使用抗纤维化药物作为引流植入物手术的辅助手段尚未证明在调节囊膜厚度方面有效。带阀植入物似乎能降低但不能消除低眼压的风险。与其他引流植入物相比,艾哈迈德瓣膜植入物更常出现滤过泡包裹。贝尔维尔德特青光眼植入物引入后,复视是一种常见并发症,但设计改进已显著降低了该并发症的发生率。
目前有几种青光眼引流植入物,所有这些植入物在降低眼压方面均已证明是安全有效的。终板较大的植入物可能实现更大程度的眼压降低,带阀植入物似乎能降低术后低眼压的风险。